| Market Capitalization (Millions $) |
9,718 |
| Shares
Outstanding (Millions) |
91 |
| Employees |
79 |
| Revenues (TTM) (Millions $) |
222 |
| Net Income (TTM) (Millions $) |
-81 |
| Cash Flow (TTM) (Millions $) |
33 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Verona Pharma Plc is a biopharmaceutical company focused on developing innovative medicines for the treatment of respiratory diseases. The company's lead product candidate, ensifentrine, is a first-in-class bronchodilator and anti-inflammatory agent that has the potential to be used in multiple respiratory conditions, including chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.
The company was founded in 2005 and is headquartered in London, UK. It has a research and development center in Cardiff, UK, and a clinical development team in the US. Verona Pharma has a global presence and operates in several countries, including the UK, US, Canada, and Australia.
Verona Pharma has a deep and experienced management team, led by CEO Dr. David Zaccardelli, who has extensive experience in drug development and commercialization. The company has a strong scientific team that has published numerous peer-reviewed articles in leading scientific journals.
Verona Pharma has a robust pipeline of product candidates, including nebulized ensifentrine for the treatment of COPD, dry powder ensifentrine for the treatment of asthma, and nebulized ensifentrine for the treatment of cystic fibrosis. The company is also developing a second-generation bronchodilator, RPL554, for the treatment of chronic obstructive pulmonary disease (COPD).
Verona Pharma is focused on bringing its innovative therapies to patients as quickly as possible. The company has a fast-paced, entrepreneurial culture and is committed to attracting and retaining top talent to drive its growth and success. Verona Pharma has a strong commitment to patient-centricity, focusing on delivering meaningful benefits to patients and their families in respiratory disease treatment.
Company Address: 3 More London Riverside London 0
Company Phone Number: 283 4200 Stock Exchange / Ticker: NASDAQ VRNA
|
5.32% 
0 %